Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 1-2 , January 2012

Prostate-specific antigen (PSA) should drive doing prostate biopsies

References 

  1. Jemal A , Siegel R , Xu J , et al.   Cancer Statistics, 2010 . CA Cancer J Clin . 2010;60:277–300
  2. American Cancer Society . Cancer Facts and Figures 2010 . http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf Accessed September 20, 2010
  3. Walter LC , Bertenthal D , Lindquist K , et al.  PSA screening among elderly men with limited life expectancies . JAMA . 2006;296:2336–2342
  4. Hugosson J , Carlsson S , Aus G , et al.  Mortality results from the Goteborg randomized population-based prostate-cancer screening trial . Lancet Oncol . 2010;11:725–732
  5. Andriole GL , Crawford ED , Grubb RL , et al.  Mortality results from a randomized prostate-cancer screening trial . N Engl J Med . 2009;360:1310–1319
  6. Pinsky PF , Andriole GL , Kramer BS , et al.  Prostate biopsy following a positive screen in the prostate, lung, colorectal, and ovarian cancer screening trial . J Urol . 2005;173:746–750 Discussion 750
  7. Schroder FH , Hugosson J , Roobol MJ , et al.  Screening and prostate-cancer mortality in a randomized European study . N Engl J Med . 2009;360:1320–1328
  8. Loeb S, Vonesh EF, Metter EJ, et al. What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing? J Clin Oncol, in press.
  9. van Leeuwen PJ , Connolly D , Gavin A , et al.  Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit . Eur J Cancer . 2010;46:377–383
  10. Smith JA . What would you do, doctor? . J Urol . 2009;182:421–422
  11. Loeb S , Roehl KA , Helfand BT , et al.  Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? . J Urol . 2010;183:112–116
  12. Carter HB , Ferrucci L , Kettermann A , et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability . J Natl Cancer Inst . 2006;98:1521–1527
  13. Jansen FH , van Schaik RH , Kurstjens J , et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection . Eur Urol . 2010;57:921–927

PII: S1078-1439(10)00328-5

doi: 10.1016/j.urolonc.2010.10.007

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 1-2 , January 2012

Article Tools